IL6 and neoplasm: Recently, IL-6 and programmed death-1-ligand 1 (PD-L1) antibody blockade combination therapy decreases pancreatic ductal adenocarcinoma (PDAC) tumor progression and increases the percentage of intratumoral effector T cells [53].